Electra Therapeutics Inc. (ETRA) vs Lyell Immunopharma, Inc. (LYEL)

A side-by-side comparison of Electra Therapeutics Inc. and Lyell Immunopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ETRA

Electra Therapeutics Inc.

$202M

$9.52HealthcareDelayed quote: Oct 6, 2026, 10:29 AM EDT

LYEL

Lyell Immunopharma, Inc.

$213M

$8.69HealthcareDelayed quote: Oct 6, 2026, 10:30 AM EDT

Total return — ETRA vs LYEL

growth of $100 · dividends reinvested · last 1y

ETRA -26.5% (-26.5%/yr)LYEL -16.0% (-16.0%/yr)LYEL compounded faster over this window

ETRA LYEL

Metrics side by side

Total return (annualized)

Metric	ETRA	LYEL
Total return (1Y)	N/A	-48.74%
Total return CAGR (3Y)	N/A	-32.73%
Total return CAGR (5Y)	N/A	-48.18%

ETRA is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full ETRA analysis Full LYEL analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.